AIpark founder Jun Yan claims there are five million street parking spaces in China's 100 largest cities that could use his car parking management system. A Gaorong Capital-led Series C round will help him reach them
Vitalbridge Capital, a Chinese venture capital firm established by Jinjian Zhang, formerly of Trustbridge Partners, has raised $150 million for its debut fund.
WorldStrides, a US-based provider of study-abroad programs for high school and university students owned by Eurazeo and Chinese private equity firm Primavera, has filed for bankruptcy protection.
Chinese insurance companies will be allowed to increase their equities exposure to up to 45% of total assets - a move that is expected to benefit private equity.
Excluded from US supply chains, China is looking to satisfy its semiconductor appetite from within. Domestic start-ups can command huge valuations, but are they sustainable?
Beijing-based Cambricon Technology, which is backed by CICC Capital, Alibaba Group, and Lenovo, has listed on the Star Market. It is the first Chinese artificial intelligence (AI) chip manufacturer to complete an IPO.
Hillhouse Capital has invested RMB10.6 billion ($1.5 billion) in Chinese electric vehicle (EV) battery manufacturer Contemporary Amperex Technology (CATL). It is part of a RMB19.7 billion capital raise by the Shenzhen-listed company.
Two more groups featuring Asian private equity executives have listed special purpose acquisition companies (SPACs) on US bourses as interest in these structures continues to rise globally.
Fidelity Investments has led a $97 million Series C round for Chinese hematology and oncology biotech developer Antengene.
Chinese electric vehicle (EV) manufacturer Xpeng Motors has closed an extended Series C round of around $500 million from a group that includes Hillhouse Capital and Sequoia Capital China, as well as hedge funds Aspex Management and Coatue Management.
Tungee, a Chinese sales-focused software-as-a-service (SaaS) platform, has raised RMB120 million ($17 million) in a Series B round led by Sequoia Capital China. Qiming Venture Partners also took part.
TuSimple, a China and US-based developer of autonomous driving technology for trucks, has received equity funding from US truck manufacturer Navistar International and entered into a partnership with the company.
Ascendum Capital Partners, a healthcare investment firm established by DCP Capital, Qiming Venture Partners and Chinese medical devices manufacturer Venus Medtech, is looking to raise $200 million for its debut fund.
Vertex Holdings’ Chua Kee-Lock likens his network of VC funds seeded by the Temasek-owned entity as a distributed computer system. It will draw down more power as it grows
PE-backed Junshi Biosciences has become the first Chinese biotech company to list in Hong Kong and the mainland, following a strong debut on Shanghai's Star Market.
Asia has seen remarkable revivals in private equity investment and fundraising – though not in exits – over the past three months. A handful of large-cap situations mask a weak environment
China-based ophthalmology therapy provider Arctic Vision has raised a $32 million Series A round led by Morningside Ventures.
The chairman and largest shareholder in scandal-hit Chinese coffee shop chain Luckin Coffee has been removed at the second attempt. Representatives of several of the company’s private equity backers have also left the board.
Hong Kong and Singapore both position themselves as the headquarters of choice for private equity firms in Asia. But the competitive dynamics – from politics to structures – are not straightforward
New Horizon Health, a China-based manufacturer of cancer testing kits for use at home, has raised $30 million in a Series E round of funding led by Rock Springs Capital.
Shanghai-based Yingke Private Equity has closed its latest renminbi-denominated fund with commitments of RMB2 billion ($286 million), primarily from insurers and other financial institutions.
Asia private equity fundraising rebounded from a seven-year low in the first quarter of the year to reach $24 billion for April through June, but commitments were concentrated on a handful of managers.
Ocumension Therapeutics, a Chinese drug developer targeting eye diseases that counts Boyu Capital and Temasek Holdings among its backers, posted a 152% gain on debut following a HK$1.5 billion ($200 million) Hong Kong IPO.
Healthcare-focused VC firm Quan Capital has led an $80 million Series A round for Citrine Medicine, a Chinese biotech developer set up by Eight Roads, F-Prime Capital, and Vivo Capital.